This rationale led to various studies demonstrating the restorative effects of low-dose IL2 therapy leading to the expansion of the Treg cell population, attenuation of other immune mediators, and improvement of disease activity in patients suffering from various autoimmune disorders, the phenomenon referred to as immunomodulation [11-13]. Here, IL2 is linked to autoimmune disease.